Entera Stock Today


USD 1.77  0.05  2.75%   

Market Performance
0 of 100
Odds Of Distress
Over 51
Entera Bio is trading at 1.77 as of the 16th of August 2022; that is -2.75 percent decrease since the beginning of the trading day. The stock's open price was 1.82. Entera Bio has 51 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Entera Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of August 2021 and ending today, the 16th of August 2022. Please note, there could be an existing legal relationship between Entera Bio (ENTX) and ENTRX CORP (ENTP). Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
28th of June 2018
Health Care
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. The company has 28.78 M outstanding shares of which 78.24 K shares are currently shorted by private and institutional investors with about 2.52 trading days to cover. More on Entera Bio

Moving together with Entera Bio

0.72MESOMesoblast Limited Fiscal Year End 30th of August 2022 PairCorr

Moving against Entera Bio

0.82KTRAKintara Therapeutics Fiscal Year End 5th of October 2022 PairCorr
0.77BPTHBio-Path Holdings Earnings Call  TodayPairCorr
0.74CVMCel-Sci Corp Fiscal Year End 28th of December 2022 PairCorr
0.65CCMConcord Medical Services Earnings Call  This WeekPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Entera Bio Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Entera Bio's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Entera Bio or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Entera Bio generated a negative expected return over the last 90 days
Entera Bio has high historical volatility and very poor performance
Entera Bio may become a speculative penny stock
Entera Bio has high likelihood to experience some financial distress in the next 2 years
Entera Bio was previously known as Entera Bio and was traded on NASDAQ Exchange under the symbol ENTXW.
The company reported the previous year's revenue of 482 K. Net Loss for the year was (13.68 M) with profit before overhead, payroll, taxes, and interest of 198 K.
Entera Bio currently holds about 20.11 M in cash with (11.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7.
Entera Bio has a poor financial position based on the latest SEC disclosures
Roughly 23.0% of the company shares are held by company insiders
Older SymbolENTXW
Related EntityENTP (ENTRX CORP)
CEOAdam Gridley
Fama & French Classification
Average Analyst Recommendation
Analysts covering Entera Bio report their recommendations after researching Entera Bio's financial statements, talking to executives and customers, or listening in on Entera Bio's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Entera Bio. The Entera consensus assessment is calculated by taking the average forecast from all of the analysts covering Entera Bio.
Strong Buy2 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Entera Bio based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Entera Bio financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares20.9 M26.1 M
Significantly Down
Slightly volatile
Weighted Average Shares Diluted21.1 M26.1 M
Significantly Down
Slightly volatile
Total Assets21.9 M26 M
Fairly Down
Slightly volatile
Total Liabilities3.5 M3.4 M
Fairly Up
Slightly volatile
Current Assets21.1 M25.3 M
Significantly Down
Slightly volatile
Current Liabilities3.4 M3.2 M
Significantly Up
Slightly volatile
Total Debt309.9 K302 K
Fairly Up
Slightly volatile
Gross Margin0.360.347
Sufficiently Up
Slightly volatile
Asset Turnover0.02350.022
Notably Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Entera Bio's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong HoldUndervalued
Financial Strength
Entera Bio's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Entera Bio's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Entera Bio's financial leverage. It provides some insight into what part of Entera Bio's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Entera Bio's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Entera Bio deploys its capital and how much of that capital is borrowed.
Entera Bio cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 240 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Entera Bio has a current ratio of 9.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Entera Bio until it has trouble settling it off, either with new capital or with free cash flow. So, Entera Bio's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Entera Bio sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Entera to invest in growth at high rates of return. When we think about Entera Bio's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(9.78 Million)
Entera Bio (ENTX) is traded on NASDAQ Exchange in USA. It is located in Kiryat Hadassah Minrav Building and employs 21 people. Entera Bio was previously known as Entera Bio and was traded on NASDAQ Exchange under the symbol ENTXW. Entera Bio is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with current market capitalization of 52.39 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Entera Bio's market, we take the total number of its shares issued and multiply it by Entera Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Entera Bio conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 28.78 M outstanding shares of which 78.24 K shares are currently shorted by private and institutional investors with about 2.52 trading days to cover. Entera Bio currently holds about 20.11 M in cash with (11.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7.
Check Entera Bio Probability Of Bankruptcy
Entera Bio holds a total of twenty-eight million seven hundred eighty thousand outstanding shares. Entera Bio retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Entera Ownership Details

Entera Stock Price Odds Analysis

What are Entera Bio's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Entera Bio jumping above the current price in 90 days from now is about 56.21%. The Entera Bio probability density function shows the probability of Entera Bio stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Entera Bio has a beta of 0.6985 suggesting as returns on the market go up, Entera Bio average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Entera Bio will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Entera Bio is significantly underperforming DOW.
  Odds Below 1.77HorizonTargetOdds Above 1.77
43.69%90 days
Based on a normal probability distribution, the odds of Entera Bio to move above the current price in 90 days from now is about 56.21 (This Entera Bio probability density function shows the probability of Entera Stock to fall within a particular range of prices over 90 days) .

Entera Bio Historical Income Statement

Entera Bio Income Statement is one of the three primary financial statements used for reporting Entera's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Entera Bio revenue and expense. Entera Bio Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Entera Bio Operating Expenses is fairly stable at the moment as compared to the past year. Entera Bio reported Operating Expenses of 12.41 Million in 2021. Research and Development Expense is likely to rise to about 6.9 M in 2022, whereas Consolidated Income is likely to drop (13.1 M) in 2022. View More Fundamentals

Entera Stock Against Markets

Picking the right benchmark for Entera Bio stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Entera Bio stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Entera Bio is critical whether you are bullish or bearish towards Entera Bio at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Entera Bio without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio File Import Now


Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module

Entera Bio Corporate Directors

Entera Bio corporate directors refer to members of an Entera Bio board of directors. The board of directors generally takes responsibility for the Entera Bio's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Entera Bio's board members must vote for the resolution. The Entera Bio board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Miranda Toledano - Independent DirectorProfile
Sean Ellis - DirectorProfile
Gerald Ostrov - Independent DirectorProfile
Chaim Davis - DirectorProfile

Invested in Entera Bio?

You need to understand the risk of investing before taking a position in Entera Bio. The danger of trading Entera Bio is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Entera Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Entera Bio. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Entera Bio is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Investing Opportunities. Note that the Entera Bio information on this page should be used as a complementary analysis to other Entera Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Entera Stock analysis

When running Entera Bio price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Is Entera Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entera Bio. If investors know Entera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entera Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
52.4 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Entera Bio is measured differently than its book value, which is the value of Entera that is recorded on the company's balance sheet. Investors also form their own opinion of Entera Bio's value that differs from its market value or its book value, called intrinsic value, which is Entera Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entera Bio's market value can be influenced by many factors that don't directly affect Entera Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entera Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine Entera Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entera Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.